Squamous cell carcinoma of the skin future or investigational therapies

Revision as of 18:11, 2 November 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-msbeih@perfuse.org +msbeih@wikidoc.org, -psingh@perfuse.org +psingh13579@gmail.com, -agovi@perfuse.org +agovi@wikidoc.org, -rgudetti@perfuse.org +ravitheja.g@gmail.com, -lbiller@perfuse.org +lbiller@wikidoc.org,...)
Jump to navigation Jump to search

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Squamous cell carcinoma of the skin Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Squamous cell carcinoma of the skin from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT Scan

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Squamous cell carcinoma of the skin future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Squamous cell carcinoma of the skin future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Squamous cell carcinoma of the skin future or investigational therapies

CDC on Squamous cell carcinoma of the skin future or investigational therapies

Squamous cell carcinoma of the skin future or investigational therapies in the news

Blogs on Squamous cell carcinoma of the skin future or investigational therapies

Directions to Hospitals Treating Squamous cell carcinoma of the skin

Risk calculators and risk factors for Squamous cell carcinoma of the skin future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]

Overview

Future or Investigational Therapies

In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]

Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.

Use of natural agents in cancer therapy is increasing. For oral squamous cell carcinoma , use of curcumin microemulsions is under considerations. New modalities like use of ultra sound mediated delivery of these microemulsions. [4]

References

  1. "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
  2. Clinuvel » Investors » FAQs
  3. PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials
  4. Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A (1988). "Dynamics of biological membranes". Ann. Ist. Super. Sanita. 24 (1): 9–21. PMID 3289448.

Template:WikiDoc Sources